Evidence map›Paper›PMID 31786653›Full record

ArticleCancer chemotherapy and pharmacology2020

Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma.

Ganessan Kichenadasse, Jim Henry Hughes, John O Miners, Arduino A Mangoni, Andrew Rowland, Ashley M Hopkins, Michael J Sorich

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Precision Dosing of Targeted Therapies Is Ready for Prime Time.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  5. Therapeutic drug monitoring of oral targeted antineoplastic drugs.European journal of clinical pharmacology · 2021
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ganessan KichenadasseDepartment of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia. ganessan.kichenadasse@flinders.edu.au.ORCID http://orcid.org/0000-0001-9923-5149
Jim Henry HughesUniversity of South Australia, North Terrace, Adelaide, SA, 5000, Australia.
John O MinersDepartment of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.
Arduino A MangoniDepartment of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.
Andrew RowlandDepartment of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.
Ashley M Hopkins *Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.
Michael J Sorich *Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.
Flinders University · AUUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose To validate a plasma vemurafenib steady-state trough concentration (C

methodsA pooled analysis of individual patient data from two advanced melanoma trials involving vemurafenib ± cobimetinib therapy was performed. Day 23 was chosen as the landmark time when steady-state concentration reached. Optimal C

resultsVemurafenib plasma concentration data were available for 402 patients who were on stable dose for the first 3 weeks. When compared to a previously described plasma vemurafenib C

conclusionA plasma vemurafenib C

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMelanomaMiddle AgedMutationProgression-Free SurvivalProportional Hazards ModelsProto-Oncogene Proteins B-rafSkin NeoplasmsTreatment OutcomeVemurafenibProto-Oncogene Proteins B-rafVemurafenibMelanomaSurvivalThreshold concentrationVemurafenib

Identifiers

PMID31786653
OpenAlexW2989926184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.